Cihangir Duy, MS, PhD

Fox Chase Cancer Center

Titles + affiliations

Assistant Professor, Cancer Epigenetics Program
Fox Chase Cancer Center

Research

Targeting LSD1 in Senescence-Like Resilient AML Cells

Summary

Despite many advances in AML therapy and initial response to treatment, most patients will eventually relapse and succumb to the disease. There is a significant need to better understand the mechanisms that enable relapse of AML for developing novel therapeutic interventions. We recently discovered that AML cells enter a senescence-like state in response to chemotherapy. This process facilitates survival of AML cells by allowing them to endure chemotherapy in a transiently dormant state while retaining the potential to repopulate leukemia. It is important to target these senescence-like dormant AML cells as they represent a pool of leukemia cells capable of initiating relapse. Hence, it is critical to identify key factors and understand the biology underlying the senescence-like leukemia cells. We identified a role of LSD1 in the senescence-like cells and will determine the functional consequence of LSD1 deficiency. Completion of this proposal will contribute to a better understanding of mechanisms regulating the senescence-like resilient phenotype in AML, which can provide a basis for future therapeutic interventions.

duy-300x300

Leukemia Research Foundation grant
$100K awarded in 2021

Disease focus
Acute myeloid leukemia (AML)

Research focus
Cancer cell biology (leukemia cell biology)